Last reviewed · How we verify

Xylocaine and Dexamethasone

University of Jordan · FDA-approved active Small molecule

Xylocaine (lidocaine) blocks nerve conduction by inhibiting sodium channels, while dexamethasone suppresses inflammatory and immune responses through glucocorticoid receptor activation.

Xylocaine (lidocaine) blocks nerve conduction by inhibiting sodium channels, while dexamethasone suppresses inflammatory and immune responses through glucocorticoid receptor activation. Used for Local anesthesia with anti-inflammatory effect (specific indication not clearly defined in available literature).

At a glance

Generic nameXylocaine and Dexamethasone
Also known asXD
SponsorUniversity of Jordan
Drug classLocal anesthetic + corticosteroid combination
TargetVoltage-gated sodium channels (lidocaine); glucocorticoid receptor (dexamethasone)
ModalitySmall molecule
Therapeutic areaPain management, Inflammation, Local anesthesia
PhaseFDA-approved

Mechanism of action

Lidocaine is a local anesthetic that reversibly inhibits voltage-gated sodium channels in nerve membranes, preventing action potential propagation and pain signal transmission. Dexamethasone is a potent corticosteroid that binds glucocorticoid receptors to reduce inflammation, suppress immune cell activation, and decrease production of inflammatory mediators. Together, this combination provides both local anesthetic and anti-inflammatory effects.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: